New data unveiled at NFID 2013 shows that intramuscular administration of NE-RSV vaccine to cotton rats delivers robust immunogenicity, high neutralizing antibodies, protection without enhanced disease

ANN ARBOR, Mich., (April 23, 2013) – NanoBio Corporation today announced that the company will present new data demonstrating positive pre-clinical results for its intramuscular (IM) respiratory syncytial virus (RSV) vaccine at the National Foundation for Infectious Diseases (NFID) 16th Annual Conference on Vaccine Research (ACVR). The new research shows that NanoBio’s intramuscular nanoemulsion-adjuvanted respiratory syncytial virus (NE-RSV) vaccine, derived from the company’s novel NanoStat® Technology, was safe and highly effective in protecting cotton rats against RSV without causing enhanced disease. NFID 2013 will take place April 22-24, 2013 in Baltimore, MD. Read more